+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rubella Recombinant Antigen Market - Global Forecast 2026-2032- Product Image
Rubella Recombinant Antigen Market - Global Forecast 2026-2032- Product Image
Sale

Rubella Recombinant Antigen Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6151559
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Rubella Recombinant Antigen Market is projected to reach USD 109.62 Million in 2026. It is expected to continue growing at a CAGR of 7.14%, reaching USD 165.80 Million by 2032.

Rubella Recombinant Antigen: Executive Overview

Rubella recombinant antigens are laboratory-produced proteins used in immunoassays, assay development, quality control, and research related to rubella virus detection and immune-response characterization. Their value is linked to reproducibility, defined composition, biosafety advantages over whole-pathogen materials, and suitability for standardized laboratory workflows. Demand is shaped by vaccination programs, congenital rubella prevention, diagnostic testing capacity, and the need for dependable reference materials.

Standardization and Multiplex Testing Are Reshaping Rubella Antigen Use

The landscape is shifting toward highly characterized recombinant proteins, improved lot-to-lot consistency, and integration into multiplex serology and automated laboratory platforms. Laboratories increasingly value antigens with documented purity, sequence information, structural relevance, and clear performance specifications. These requirements support more comparable results across sites while encouraging suppliers and assay developers to strengthen validation, traceability, and documentation.

Artificial Intelligence Is Strengthening Assay Design and Quality Control

Artificial intelligence can support epitope-selection workflows, protein-expression optimization, sequence comparison, image interpretation, and anomaly detection in laboratory quality systems. Its practical contribution depends on representative training data, transparent validation, and expert review, particularly where antibody cross-reactivity or changing viral lineages may affect interpretation. AI is therefore best viewed as an augmentation tool for antigen design, test development, and quality assurance rather than a replacement for laboratory verification.

Regional Insights: Prevention Programs and Laboratory Capacity Shape Adoption

North America and Europe generally benefit from mature laboratory infrastructure, established vaccination surveillance, and strong expectations for documentation and analytical validation. Asia-Pacific combines expanding diagnostic capacity with substantial variation in access, making scalable and robust assay formats important. Latin America continues to prioritize congenital rubella prevention and surveillance while managing uneven laboratory resources. The Middle East shows differing national capabilities and procurement environments, with demand influenced by public-health laboratory strengthening. Africa’s needs are closely tied to immunization coverage, outbreak surveillance, workforce capacity, and access to reliable testing materials.

Group Insights: Alliances and Economic Blocs Influence Standards and Access

ASEAN countries present diverse regulatory systems and laboratory capabilities, creating opportunities for harmonized procurement and shared quality practices. BRICS members span major research, manufacturing, and public-health systems, but differ in regulatory maturity and access to specialized reagents. The European Union emphasizes coordinated safety, quality, and diagnostic requirements through its regional regulatory environment. G7 members typically support advanced research infrastructure and stringent evidence expectations. GCC markets often combine sophisticated central laboratories with imported supply chains, while NATO countries may benefit from stronger preparedness coordination and interoperability priorities, although national procurement and regulatory processes remain distinct.

Country Insights: National Programs and Research Capacity Create Distinct Priorities

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally emphasize validated diagnostics, surveillance quality, and integration with advanced laboratory systems. China and India combine large public-health needs with expanding domestic research and manufacturing capabilities, while regulatory and regional implementation conditions can vary. Brazil and Mexico continue to balance vaccination and congenital rubella surveillance priorities with differences in laboratory access across territories. Russia’s requirements are shaped by national laboratory networks, public-health policy, and local supply considerations. Across these countries, adoption is most likely where recombinant antigens demonstrate reproducibility, documented analytical performance, and compatibility with existing workflows.

Industry Priorities: Build Evidence, Resilience, and Interoperability

Industry leaders should establish clear antigen characterization packages covering identity, purity, expression system, stability, and lot consistency. They should validate performance across relevant specimen types and platforms, monitor cross-reactivity, and maintain transparent change-control procedures. Supply resilience can be improved through qualified backup sources, secure cold-chain or storage practices where required, and regionally appropriate technical support. Collaboration with public-health laboratories and diagnostic developers can help align products with surveillance needs, while responsible AI use should include data governance, human oversight, and independently reviewed performance claims.

Research Methodology: Evidence-Based Synthesis of Market Drivers

This executive summary uses the supplied market definition-rubella recombinant antigen-and organizes the analysis around documented scientific, public-health, regulatory, and laboratory-system considerations. It distinguishes established applications and structural drivers from forward-looking possibilities, avoids unsupported numerical claims, and treats regional, group, and country conditions as heterogeneous. The assessment emphasizes reproducibility, assay validation, vaccination and surveillance needs, laboratory capacity, procurement, and quality requirements rather than market estimates or company-level comparisons.

Conclusion: Reliable Antigens Support Better Rubella Surveillance and Testing

Rubella recombinant antigens occupy an important role in standardized serology, assay development, and laboratory quality programs. Their relevance is reinforced by the continuing need to detect infection accurately, monitor immunity, and support congenital rubella prevention. Progress will depend on well-characterized materials, rigorous validation, resilient supply arrangements, and responsible use of digital and AI-enabled tools. Organizations that align technical performance with regional public-health realities will be better positioned to support dependable rubella testing and surveillance.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Rubella Recombinant Antigen Market, by Product Type
7.1. Introduction
7.2. Combination
7.3. Monovalent
8. Rubella Recombinant Antigen Market, by Formulation
8.1. Introduction
8.2. Liquid
8.3. Lyophilized
9. Rubella Recombinant Antigen Market, by Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Rubella Recombinant Antigen Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Research Institutes
11. Rubella Recombinant Antigen Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Rubella Recombinant Antigen Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Rubella Recombinant Antigen Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abcam plc
15.2. Abcam plc
15.3. Becton, Dickinson and Company
15.4. Bio-Rad Laboratories, Inc.
15.5. Bio-Techne Corporation
15.6. Creative Biomart
15.7. Creative Diagnostics
15.8. Enzo Life Sciences
15.9. F. Hoffmann-La Roche AG
15.10. GenScript Biotech Corporation
15.11. GenScript Biotech Corporation
15.12. Merck KGaA
15.13. PerkinElmer, Inc.
15.14. PerkinElmer, Inc.
15.15. QIAGEN N.V.
15.16. RayBiotech, Inc
15.17. SERION Diagnostics
15.18. Sino Biological Inc.
15.19. Thermo Fisher Scientific Inc.
15.20. Trinity Biotech plc
15.21. Vircell, S.L.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Rubella Recombinant Antigen Market, Years Considered for the Study
FIGURE 2. Global Rubella Recombinant Antigen Market, Research Design
FIGURE 3. Global Rubella Recombinant Antigen Market, Research Framework
FIGURE 4. Global Rubella Recombinant Antigen Market, Data Triangulation
FIGURE 5. Global Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Rubella Recombinant Antigen Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Rubella Recombinant Antigen Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Rubella Recombinant Antigen Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 9. Global Rubella Recombinant Antigen Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Rubella Recombinant Antigen Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 11. Global Rubella Recombinant Antigen Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Rubella Recombinant Antigen Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Rubella Recombinant Antigen Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Rubella Recombinant Antigen Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Rubella Recombinant Antigen Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Rubella Recombinant Antigen Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Rubella Recombinant Antigen Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Rubella Recombinant Antigen Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Rubella Recombinant Antigen Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Rubella Recombinant Antigen Market Segmentation & Coverage
TABLE 2. Global Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 3. Global Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Combination Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Combination Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Combination Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Monovalent Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Monovalent Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Monovalent Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 11. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Lyophilized Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Lyophilized Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Lyophilized Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 18. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 28. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Rubella Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Asia-Pacific Rubella Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Asia-Pacific Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 40. Asia-Pacific Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 41. Asia-Pacific Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 42. Asia-Pacific Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 43. North America Rubella Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. North America Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 45. North America Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 46. North America Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 47. North America Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 48. Latin America Rubella Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Latin America Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 50. Latin America Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 51. Latin America Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 52. Latin America Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Europe Rubella Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Europe Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 55. Europe Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 56. Europe Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 57. Europe Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 58. Middle East Rubella Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Middle East Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 60. Middle East Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 61. Middle East Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 62. Middle East Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 63. Africa Rubella Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Africa Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 65. Africa Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 66. Africa Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 67. Africa Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. Global Rubella Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. ASEAN Rubella Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. ASEAN Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 71. ASEAN Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 72. ASEAN Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 73. ASEAN Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. GCC Rubella Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. GCC Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 76. GCC Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 77. GCC Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 78. GCC Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. European Union Rubella Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. European Union Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 81. European Union Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 82. European Union Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 83. European Union Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. BRICS Rubella Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. BRICS Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 86. BRICS Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 87. BRICS Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 88. BRICS Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. G7 Rubella Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. G7 Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. G7 Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 92. G7 Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 93. G7 Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. NATO Rubella Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. NATO Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 96. NATO Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 97. NATO Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 98. NATO Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Global Rubella Recombinant Antigen Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. United States Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 101. United States Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 102. United States Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 103. United States Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 104. United States Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Canada Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 106. Canada Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. Canada Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 108. Canada Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 109. Canada Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Mexico Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 111. Mexico Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 112. Mexico Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 113. Mexico Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 114. Mexico Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. Brazil Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 116. Brazil Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 117. Brazil Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 118. Brazil Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 119. Brazil Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. United Kingdom Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 121. United Kingdom Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 122. United Kingdom Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 123. United Kingdom Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 124. United Kingdom Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Germany Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 126. Germany Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. Germany Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 128. Germany Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 129. Germany Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. France Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 131. France Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. France Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 133. France Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 134. France Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Russia Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 136. Russia Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 137. Russia Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 138. Russia Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 139. Russia Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. Italy Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 141. Italy Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 142. Italy Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 143. Italy Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 144. Italy Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Spain Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 146. Spain Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 147. Spain Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 148. Spain Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 149. Spain Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. China Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 151. China Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. China Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 153. China Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 154. China Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. India Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 156. India Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 157. India Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 158. India Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 159. India Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Japan Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 161. Japan Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 162. Japan Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 163. Japan Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 164. Japan Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Australia Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 166. Australia Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 167. Australia Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 168. Australia Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 169. Australia Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. South Korea Rubella Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 171. South Korea Rubella Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 172. South Korea Rubella Recombinant Antigen Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 173. South Korea Rubella Recombinant Antigen Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 174. South Korea Rubella Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Global Rubella Recombinant Antigen Market Share, by Key Player, 2025
TABLE 176. Global Rubella Recombinant Antigen Market, Key Experts

Companies Mentioned

  • Abcam plc
  • Abcam plc
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Creative Biomart
  • Creative Diagnostics
  • Enzo Life Sciences
  • F. Hoffmann-La Roche AG
  • GenScript Biotech Corporation
  • GenScript Biotech Corporation
  • Merck KGaA
  • PerkinElmer, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • RayBiotech, Inc
  • SERION Diagnostics
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
  • Vircell, S.L.

Related Topics

Related Reports

Animal Biotechnology Market - Global Forecast 2026-2032 - Product Image

Animal Biotechnology Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Polyclonal Antibodies Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Polyclonal Antibodies Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Polyclonal Antibody Reagent Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Polyclonal Antibody Reagent Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Primary Antibody Market Report 2026 - Product Image

Primary Antibody Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Polyclonal Antibodies Market - Global Strategic Business Report - Product Image

Polyclonal Antibodies Market - Global Strategic Business Report

  • Report
  • 462 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.